このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

HCV関連肝線維症のスペクトル全体にわたる微生物移動に関与するメカニズムの解読

HCV関連肝線維症のスペクトル全体にわたる微生物移動に関与するメカニズムを解読するための学際的なアプローチ

Background:

- Hepatitis C infection (HCV) is a leading cause of liver disease. Normal bacteria from the intestines may spread to the liver and blood during liver disease. This is called bacterial translocation (BT). Researchers think BT may cause liver disease to worsen.

Objectives:

- To study the mechanisms involved in BT in early and advanced liver disease. To find out whether BT causes liver disease to worsen.

Eligibility:

- People over age 18 with HCV and clinically stable liver disease.

Design:

  • Participants will be screened with medical history and physical exam. They will have blood tests and imaging studies.
  • Participants will have 2 outpatient visits and a 3-day stay at the clinic.
  • At visit 1, participants will have urine and blood tests. They will have a magnetic resonance imaging (MRI) scan. A solution will be injected into a vein. The MRI scanner is a metal cylinder surrounded by a magnetic field. The participant will lie on a table that slides in and out of the cylinder.
  • At visit 2, a substance will be injected into a vein and swallowed. Participants will then have blood drawn 5 times over 90 minutes.
  • During the inpatient stay, serial blood tests will be drawn.
  • Participants will give 2 stool samples and have another MRI.
  • A needle will be inserted through the chest wall into a vein inside the liver, guided by ultrasound. The blood pressure inside this vein will be measured and blood will be drawn from it. About 1 inch of liver tissue will be removed.
  • A study investigator will call participants to discuss all test results.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

Hepatitis C (HCV) is a leading cause of cirrhosis worldwide. Most complications associated with cirrhosis are driven by an altered portal circulation and the development of portal hypertension. Bacterial translocation (BT) from the gut to the systemic circulation is considered a pivotal mechanism contributing to the development of life-threatening complications in end stage cirrhosis. Recent evidence suggests that the liver and systemic circulation may be exposed to gut derived microbial products at earlier stages of liver disease. This early exposure may trigger hepatic inflammation, modify immune host response and accelerate hepatic fibrogenesis; which, in turn, impairs portal inflow, alters the portal circulation, and leads to development of portal hypertension. The mechanisms resulting in systemic exposure to gut derived microbial products, and the subsequent host response to BT has not been studied in patients with early liver disease nor fully compensated cirrhosis.

We therefore intend to enroll 30 chronic HCV patients with either cirrhosis (20) or minimal liver fibrosis (10). Study participants will undergo extensive evaluation with portal vein sampling and pressure measurements, dual cholate clearances, liver biopsy, serologic, immunologic, fecal microbiome and imaging studies. This will be followed by an optional second percutaneous liver biopsy and portal vein sampling 9-15 months after HCV treatment. The treatment protocol is a separate independent protocol, 15-DK- 0143 utilizing Sofosbuvir and GS-5816. The goals of our study are to characterize the extent of BT in early stages of cirrhotic and non-cirrhotic liver disease, explore the mechanisms contributing to its occurrence and identify potential serological, immunological and hemodynamic biomarkers associated with chronic infection. This, in turn, can aid in establishing a possible link between BT, subsequent host responses and severity of liver disease.

研究の種類

観察的

入学 (実際)

30

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • National Institutes of Health Clinical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Primary clinical patients with chronic HCV infection divided into 2 groups according to liver fibrosis stage.

説明

  • INCLUSION CRITERIA:

    1. All age greater than 18 male or female
    2. Capacity to provide written informed consent
    3. Evidence of HCV RNA in 2 serum samples at least 6 months apart.
    4. All HCV genotypes
    5. Liver biopsy in the last 2 years prior to enrollment showing Ishak fibrosis score of either 0-1 or 5-6. An alternative to liver biopsy will be a Fibroscan study performed in the 6 months prior to study enrollment showing a score of either kPa <7 or above 13.
    6. Child-Pugh score less than or equal to 6
    7. Prior to each liver biopsy and portal vein cannulation procedure, blood will be drawn for CBC, PT/INR & acute care panel.

EXCLUSION CRITERIA:

  1. Pregnant women or females at child bearing age not taking measures to prevent pregnancy during the period of study

  2. Patients currently on treatment for hepatitis C

  3. Clinical, serologic or histopathologic evidence supporting other etiologies of chronic liver disease besides HCV

  4. Current or past clinical evidence of decompensated liver disease (e.g. ascites, bleeding esophageal varices, spontaneous bacterial peritonitis, encephalopathy etc.)

  5. Cross sectional liver imaging study from the past 6 months showing a focal lesion suspicious of hepatocellular carcinoma and/or alpha-fetoprotein level greater than 200 ng/mL.

  6. Patients with active bacterial, viral or fungal, systemic or localized infection.

  7. Antibiotic treatment 30 days prior to study enrollment

  8. History of chronic inflammatory diseases of the bowel (Crohn s disease, Ulcerative colitis and celiac disease)

  9. History of congestive heart failure of moderate to severe degree.

  10. History of non-cirrhotic portal hypertension or portal vein thrombosis

  11. Patients with severe allergic reactions to iodine contrast, which cannot be controlled by premedication with antihistamines and steroids.

  12. EXCLUSION CRITERIA FOR MRI:

    12.1 Subjects with contraindication to MRI scanning. These contraindications include but are not limited to the following devices or conditions:

    <TAB>a. Implanted cardiac pacemaker or defibrillator

    <TAB>b. Cochlear Implants

    <TAB>c. Ocular foreign body (e.g. metal shavings)

    <TAB>d. Embedded shrapnel fragments

    <TAB>e. Central nervous system aneurysm clips

    <TAB>f. Implanted neural stimulator

    <TAB>g. Medical infusion pumps

    <TAB>h. Any implanted device that is incompatible with MRI.

    12.2 Unsatisfactory performance status as judged by the referring physician such that the subject could not tolerate an MRI scan. Examples of medical conditions that would not be accepted would include unstable angina and dyspnea at rest.

    12.3 Subjects requiring sedation for MRI studies.

    12.4 Subjects with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.).

    12.5 Pregnant or lactating women.

    12.6 Subjects with severe back-pain or motion disorders who will be unable to tolerate supine positioning within the MRI scanner and hold still for the duration of the examination.

    12.7 For Gadolinium based and SPIO MRI Use:

    <TAB>a. History of severe allergic reaction to these contrast agents despite the use of premeditation with an anti-histaminic and cortisone.

    <TAB>b. eGFR < 60 ml/min/1.73m^2

  13. Absolute neutrophil count below 1000/mm^3, Hemoglobin level below 10.0 g/dl or platelet count lower than 70,000/mm^3.

  14. INR greater than or equal to 1.5, PTT greater than or equal to 1.3 times control and/or any known history of disease associated with increased bleeding diathesis.

  15. Serum creatinine greater than or equal to 2.0 mg/dl unless the measured creatinine clearance is greater than 60 mL/min

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:CASE_ONLY
  • 時間の展望:CROSS_SECTIONAL

コホートと介入

グループ/コホート
介入・治療
Group A

Patients with fibrosis levels spanning from bridging fibrosis to cirrhosis (Ishak fibrosis score 5-6)

test for defining disease severity

Group B

Patients with minimal fibrosis (Ishak score 0-1).

test for defining disease severity

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Microbial product detection rate
時間枠:Before anti viral therapy and 9-15 months after treatment

Assess the extent of BT, explore possible mechanisms accounting for its occurrence and evaluate its effects on the immune system in different stages of liver fibrosis

Before anti viral therapy and 9-15 months after treatment

二次結果の測定

結果測定
メジャーの説明
時間枠
Dual-cholate liver function tests
時間枠:Baseline, and 9-15 months after treatment

Comparison of dual-cholate liver function tests and its association with microbial product levels in portal and systemic blood, between group A and group B patients.

Baseline, and 9-15 months after treatment
SPIO-MRI Kupffer cell uptake
時間枠:Baseline, and 9-15 months after treatment

Comparison of SPIO-MRI Kupffer cell uptake values and its association with microbial product levels in portal and systemic blood between group A and group B patients.

Baseline, and 9-15 months after treatment
Immune activation markers
時間枠:Baseline, and 9-15 months after treatment

Comparison of immune activation markers to bacterial products in liver tissue between group A and group B patients before and after HCV treatment.

Baseline, and 9-15 months after treatment
Pro and anti-inflammatory gene transcription
時間枠:Baseline, and 9-15 months after treatment

Comparison of pro and anti-inflammatory gene transcription analysis in between group A and group B patients

Baseline, and 9-15 months after treatment
Fecal microbiome
時間枠:Baseline, and 9-15 months after treatment

Comparison of fecal microbiome analysis between group A and group B patients

Baseline, and 9-15 months after treatment
Species homology
時間枠:Baseline, and 9-15 months after treatment

Evaluation of species homology between microbial DNA identified in portal and systemic blood and fecal samples by deep sequencing.

Baseline, and 9-15 months after treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Theo Heller, M.D.、National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2015年5月29日

一次修了 (実際)

2017年2月24日

研究の完了 (実際)

2017年4月25日

試験登録日

最初に提出

2015年3月26日

QC基準を満たした最初の提出物

2015年3月26日

最初の投稿 (推定)

2015年3月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年3月31日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 150100
  • 15-DK-0100

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。